+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07301268

Study of GI-102 Alone or With Pembrolizumab Before Surgery in Adults With Recurrent or Progressive IDH Wildtype Glioblastoma and Grade 4 Astrocytoma

Led by Mayo Clinic · Updated on 2026-10-30

36

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of the drug GI-102 alone and in combination with pembrolizumab in patients with recurrent or progressive IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma. This phase II trial studies whether giving these treatments before surgery can safely alter tumor growth and improve outcomes. Glioblastoma is a common and aggressive brain tumor, and current treatments include surgery, radiation, and chemotherapy. The study aims to explore new immune-based therapies in this challenging condition. Participants receive GI-102 intravenously on day 1 of cycle 1, followed by surgery 14 days later. In one group, pembrolizumab is added starting with cycle 2, given every 21 days along with GI-102 for up to two years if there is no disease progression or unacceptable side effects. Patients undergo multiple procedures such as echocardiography or MUGA scans before treatment, along with blood collection and MRI or CT scans throughout the study to monitor their condition. Throughout the trial, participants are closely followed with laboratory tests and imaging to assess changes in tumor markers, overall survival, and side effects. The main outcome is the change in pharmacodynamic markers in tumor tissue over up to two years. Safety is monitored for 90 days after the last dose, with survival tracked for up to five years. The study requires participants to provide consent and be willing to return for follow-up visits during active monitoring.

CONDITIONS

Brief Title

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Research Team

C

Clinical Trials Referral Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here